Irish diagnostics company, Diaceutics, has announced a collaboration with computer manufacturer Lenovo, and chip manufacturer Intel.
Diaceutics will work with the companies using AI to see whether patients can be grouped together according to diagnostic test information. The company hopes that by doing this, it can identify ways to improve diagnosis, treatment and outcomes for patients with similar characteristics.
Diaceutics hopes that by using Lenovo and Intel’s technology, alongside testing data from hundreds of clinical laboratories, it can get the the right medicine to the right individuals at the right time by classifying patient groups and disease patterns.
The machine learning system will use biomarkers covering a variety of tumours and cancer types to identify similarities and patterns to highlight what is happening among groups of patients. By organising this information, at-risk patients could be identified, diagnosed and treated much faster.
Peter Keeling, chief executive officer, Diaceutics said: “Artificial intelligence can make a very strong and positive impact on precision medicine and we are excited to be moving the boundaries with this highly innovative technology.
“We can now look at data in a novel way. No longer will we only be making decisions based on diagnostic data. Artificial intelligence allows us to look at the complete patient journey from initial testing and diagnosis, and on to the ultimate treatment. The result will be significantly better patient testing and likely improved patient outcomes, such as longer cancer survivorship rates.
“This collaboration is a major step in our mission to help patients, by helping them find the right precision medicine at the right time. We are using artificial intelligence to enable the world to unlock the true life changing promise of precision medicine.”